Current and Future Treatments for Diabetic Retinopathy
The pathogenesis of diabetic retinopathy in humans remains imperfectly understood; in particular, the kinetics of the various pathogenic events in the very early stages of retinal damage are difficult to recognize [...]
Saved in:
Main Authors: | Francine Behar-Cohen (Author), Anat Loewenstein (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2022-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Intravitreal Anti-Vascular Endothelial Growth Factor Agents for the Treatment of Diabetic Retinopathy: A Review of the Literature
by: Irini Chatziralli, et al.
Published: (2021) -
Current Treatments and Innovations in Diabetic Retinopathy and Diabetic Macular Edema
by: Jesus H. Gonzalez-Cortes, et al.
Published: (2022) -
Current Trends in the Monitoring and Treatment of Diabetic Retinopathy in Young Adults
by: Dorota Raczyńska, et al.
Published: (2014) -
Long-Term Oral Treatment with Non-Hypoglycemic Dose of Glibenclamide Reduces Diabetic Retinopathy Damage in the Goto-KakizakiRat Model
by: Marianne Berdugo, et al.
Published: (2021) -
Evaluation of an Intravitreal Rho-Associated Kinase Inhibitor Depot Formulation in a Rat Model of Diabetic Retinopathy
by: Cecile Lebon, et al.
Published: (2021)